Open-angle glaucoma is a chronic optic neuropathy in which drainage angle remains open but aqueous outflow is impaired, leading to progressive optic nerve damage and visual field loss.
Life Biosciences has treated the first patient with ER-100, a cell-rejuvenating gene therapy for glaucoma. The FDA-approved Phase 1 trial will assess safety in up to 18 patients.
A stem cell therapy for geographic atrophy improved vision in a phase Ib trial, and the first gene therapy for optic neuropathies was administered. Next-generation anti-VEGF agents are also extending treatment intervals in retinal vascular disease.
Nicox SA received positive written feedback from a pre-NDA meeting with the FDA for NCX 470, a nitric oxide-donating bimatoprost eye drop for glaucoma. The NDA submission remains on track for summer 2026.
Ocular Therapeutix announced positive topline results from SOL-1, its Phase 3 superiority trial of AXPAXLI for wet age-related macular degeneration, meeting primary and durability endpoints with high statistical significance.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07619482 |
Topical Insulin for Glaucoma (TING2) |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07325240 |
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients |
RECRUITING | PHASE4 |
| NCT07228221 |
Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma |
RECRUITING | PHASE4 |
| NCT07082816 |
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction |
COMPLETED | PHASE3 |
| NCT06993311 |
Real World Evidence of Xen45 Gel Implant in Pseudoexfoliation Glaucoma |
COMPLETED | |
| NCT06883123 |
Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost |
RECRUITING | PHASE4 |
| NCT06851546 |
Efficacy of Selective Laser Trabeculoplasty Targeting Nasal Versus Inferior 180-degree |
COMPLETED | NA |
| NCT06666855 |
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06614218 |
MIMS® Retrospective Chart Review |
NOT_YET_RECRUITING | |
| NCT06612346 |
Minimally Invasive Nasal Trabeculostomy: Long-Term Follow-Up Extension Study |
COMPLETED |
